Facile Synthesis and Cytotoxicity of Phenazine-Chromene Hybrid Molecules Derived from Phenazine Natural Product
-
Published:2019-05-03
Issue:1
Volume:22
Page:35-40
-
ISSN:1386-2073
-
Container-title:Combinatorial Chemistry & High Throughput Screening
-
language:en
-
Short-container-title:CCHTS
Author:
Zhang Mei-Chen1, Gu Shu-Hui1, Liu Guang-Pan2, Li Chen-Cheng2, Xu Han-Mei2, Wu Zhong-Xi1, Ye Bo-Ping3, Lu Yuan-Yuan3, Huang De-Chun1, Wang Zhi-Xiang1, Jiang Feng1
Affiliation:
1. School of Engineering, China Pharmaceutical University, Nanjing 210009, China 2. The Engineering Research Center of Peptide Drug Discovery and Development, China Pharmaceutical University, Nanjing 210009, China 3. School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, China
Abstract
Aim and Objective:
Small molecule targeted drugs can effectively reduce the toxicity
and side effects of drugs, and improve the efficacy of drugs by their specific antitumor activity.
Hence, the development of small molecular targeted drugs for cancer has important significance.
This study was undertaken to design and synthesize novel phenazine-chromene hybrid molecules
in order to optimize the structure and improve the efficacy of this kind of hybrids.
Materials and Methods:
O-diaminobenzene was used as starting material to synthesize twentyfour
heterocyclic compounds designed as hybrid molecules of phenazine and 4H-chromene
pharmacophores by facile methods. The structures of the compound were confirmed by 1H NMR,
13C NMR and HRMS. Furthermore, the synthesized compounds were evaluated for in vitro activity
against four human cancer cell lines and two non-cancer cell lines by MTT test.
Results:
Some compounds showed strong cytotoxic activities against HepG2 and A549 cancer
lines (IC50 = 5-10 µM). Comparing 2i with 2l, the introduction of hydrophilic groups on the
phenazine core could not improve the antiproliferative activity significantly. Except 2d and 3c,
compounds owning chlorine substituent on the 4H-chromene pharmacophore seemingly contribute
to enhance the compounds’ antiproliferative activity. Specially, compound 3c showed highest
cytotoxicity against A549 cells with IC50 values of 3.3±0.4 µM. Furthermore, all compounds
showed low or no cytotoxicity against HUVEC and L02 non-cancer cells in vitro.
Conclusion:
Compound 3c may be used as potential lead molecule against A549 cancer cells.
Funder
Fundamental Research Funds for the Central Universities National Key R&D Program of China National Natural Science Foundation of China
Publisher
Bentham Science Publishers Ltd.
Subject
Organic Chemistry,Computer Science Applications,Drug Discovery,General Medicine
Reference24 articles.
1. Ali I, Haque A, Saleem K. Bioorg Med Chem, Hsieh, Ming, F. Curcumin-I Knoevenagel’s condensates and their Schiff’s bases as anticancer agents: Synthesis, pharmacological and simulation studies.,, 2013, 21,, 3808-3820, 2. Ali I, Lone MN, Al-Othman ZA, Al-Warthan A, Sanagi MM. Curr Drug Targets, Heterocyclic scaffolds: Centrality in anticancer drug development.,, 2015, 16,, 711-734, 3. Ali I, Wani WA, Haque A, Saleem K. Future Med Chem, Glutamic acid and its derivatives: candidates for rational design of anticancer drugs.,, 2013, 5,, 961-978, 4. Ali I, Wani WA, Saleem K, Haque A. Anticancer Agents Med Chem, Platinum compounds: A hope for future cancer chemotherapy.,, 2013, 13,, 296-306, 5. Ali I, Wani WA, Saleem K, Haque A. Curr Drug Ther, Thalidomide: A banned drug resurged into future anticancer drug.,, 2012, 7,, 13-23,
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|